Elite Plans Opioid NDA Submission After Phase III Success
This article was originally published in Scrip
Elite Pharmaceuticals plans to submit a new drug application (NDA) to the US FDA by the end of this year based on positive Phase III results in the treatment of moderate to severe pain for ELI-200, an opioid-based pill designed with the company's proprietary abuse-deterrent technology (ART).
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.